AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Vect-Horus enters into Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd.

March 26, 2019

MARSEILLE, France--(BUSINESS WIRE)--Mar 26, 2019--Vect-Horus S.A.S. (Marseille, France) announced today that Vect-Horus and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration and license agreement, focused on the development of novel molecules targeting neurodegenerative diseases.

Under the agreement, Vect-Horus will receive research fees, success-based milestones on the research and development progress, as well as royalties on sales of the products.

Vect-Horus will apply its proprietary VECTrans® technology, which facilitates the transport of drugs into the brain, to Ono’s therapeutic molecules. Vect-Horus will utilize its expertise to conjugate these therapeutic molecules with its peptide vectors and demonstrate improved brain uptake and efficacy in animals. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical products arising out of the drug discovery collaboration.

“We are delighted to partner with Ono, one of the oldest pharmaceutical companies in the world and an important developer of innovative drugs,” commented Alexandre Tokay, Chief Executive Officer and cofounder of Vect-Horus. “Our agreement with Ono strengthens our long-standing commitment to improve, using our technology, the brain delivery of therapeutic molecules and bring forward novel therapies that address critical unmet needs.”

About Vect-Horus
Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (including the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules.
Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. To learn more about Vect-Horus, visit www.vect-horus.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190326005021/en/

CONTACT: Vect-Horus :

Elodie Dormes

Business Development Manager

contact@vect-horus.com

KEYWORD: EUROPE ASIA PACIFIC FRANCE JAPAN

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Vect-Horus

Copyright Business Wire 2019.

PUB: 03/26/2019 06:00 AM/DISC: 03/26/2019 06:00 AM

http://www.businesswire.com/news/home/20190326005021/en

All contents © copyright 2019 The Associated Press. All rights reserved.